Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kwak, Kihyuck ^a   Jiang, Rosie ^a   Wang, Joshua W ^a   Jagu, Subhashini ^a   Kirnbauer, Reinhard ^b   Roden, Richard B S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L2 ANTIBODY; CARRAGEENAN; FURIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HEPARIN; NEUTRALIZING ANTIBODY; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTISERUM; CAPSID PROTEIN; LUCIFERASE; SECRETASE; VIRUS ANTIGEN; WART VIRUS VACCINE;

ALPHAPAPILLOMAVIRUS; ARTICLE; BETAPAPILLOMAVIRUS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INFECTION PREVENTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN CLEAVAGE; VIRAL TROPISM; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; ANTAGONISTS AND INHIBITORS; GENETICS; HELA CELL LINE; HUMAN; IMMUNOLOGY; NONPARAMETRIC TEST; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; SERODIAGNOSIS; VIRULENCE; WESTERN BLOTTING;

ALPHAPAPILLOMAVIRUS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIGENS, VIRAL; BETAPAPILLOMAVIRUS; BLOTTING, WESTERN; CAPSID PROTEINS; CARRAGEENAN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FURIN; HELA CELLS; HEPARIN; HUMANS; IMMUNE SERA; LUCIFERASES; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; VIRULENCE;

EID: 84901196608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097232     Document Type: Article

References (58)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
2. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2: 342-350.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527. (Pubitemid 36159887)
4. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285. (Pubitemid 38924707)
5. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24 Suppl 3: S11-25. (Pubitemid 44404053)
6. Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Disease markers 23: 247-259. (Pubitemid 47015794)
7. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, et al. (1991) Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 60: 1445-1456.
8. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82: 5190-5197. (Pubitemid 351705228)
9. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5: 557-567.
10. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, et al. (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274: 5810-5822. (Pubitemid 29109237)
11. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human Papillomavirus Infection Requires Cell Surface Heparan Sulfate. J Virol 75: 1565-1570. (Pubitemid 32094716)
12. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2: e69.
13. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861. (Pubitemid 47038188)
14. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
15. Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT (2011) Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. Journal of the National Cancer Institute 103: 737-743.
16. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, et al. (2007) Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. The Journal of biological chemistry 282: 27913-27922. (Pubitemid 47529517)
17. Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, et al. (2011) The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral therapy 16: 1219-1226.
18. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, et al. (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70: 5875-5883. (Pubitemid 26266799)
19. Roden RB, Day PM, Bronzo BK, Yutzy WHt, Yang Y, et al. (2001) Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol 75: 10493-10497. (Pubitemid 32948081)
20. Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103: 1522-1527. (Pubitemid 43191198)
21. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM (2009) The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 106: 20458-20463.
22. Bienkowska-Haba M, Patel HD, Sapp M (2009) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.
23. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, et al. (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE 7: e43519.
24. Bossis I, Roden RB, Gambhira R, Yang R, Tagaya M, et al. (2005) Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. Journal of virology 79: 6723-6731. (Pubitemid 40677303)
25. Bergant Marusic M, Ozbun MA, Campos SK, Myers MP, Banks L (2012) Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 13: 455-467.
26. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, et al. (2006) A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80: 759-768. (Pubitemid 43062888)
27. Karanam B, Peng S, Li T, Buck C, Day PM, et al. (2010) Papillomavirus infection requires gamma secretase. J Virol 84: 10661-10670.
28. Huang HS, Buck CB, Lambert PF (2010) Inhibition of gamma secretase blocks HPV infection. Virology 407: 391-396.
29. Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6: 753-763. (Pubitemid 44450464)
30. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
31. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
32. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The lancet oncology 13: 100-110.
33. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet infectious diseases 12: 781-789.
34. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
35. Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, et al. (2013) Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 87: 6127-6136.
36. Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, et al. (2013) Optimization of Multimeric Human Papillomavirus L2 Vaccines. PLoS ONE 8: e55538.
37. Mistry N, Wibom C, Evander M (2008) Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism. Virology journal 5: 118.
38. Cruz L, Meyers C (2013) Differential Dependence on Host Cell Glycosaminoglycans for Infection of Epithelial Cells by High-Risk HPV Types. PLoS ONE 8: e68379.
39. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119: 445-462.
40. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I (1999) Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 73: 4972-4982. (Pubitemid 29246758)
41. Leder C, Kleinschmidt JA, Wiethe C, Muller M (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75: 9201-9209. (Pubitemid 32851924)
42. Johansson C, Schwartz S (2013) Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nature reviews Microbiology 11: 239-251.
43. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216. (Pubitemid 38406035)
44. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2006) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology.
45. Senger T, Schadlich L, Textor S, Klein C, Michael KM, et al. (2010) Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 28: 1583-1593.
46. Faust H, Andersson K, Forslund O, Dillner J (2013) Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. The Journal of general virology 94: 1096-1103.
47. Kwak K, Jiang R, Jagu S, Wang JW, Wang C, et al. (2013) Multivalent human papillomavirus L1 DNA vaccination utilizing electroporation. PLoS ONE 8: e60507.
48. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Muller L, et al. (2013) High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS ONE 8: e75677.
49. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. The Journal of cell biology 106: 761-771. (Pubitemid 18089976)
50. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, et al. (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. Journal of virology 77: 13125-13135. (Pubitemid 37494308)
51. Patterson NA, Smith JL, Ozbun MA (2005) Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79: 6838-6847. (Pubitemid 40677316)
52. Cerqueira C, Liu Y, Kuhling L, Chai W, Hafezi W, et al. (2013) Heparin increases the infectivity of Human Papillomavirus Type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cellular microbiology.
53. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, et al. (2011) Structural basis of oligosaccharide receptor recognition by human papillomavirus. The Journal of biological chemistry 286: 2617-2624.
54. Roden R, Monie A, Wu TC (2006) The impact of preventive HPV vaccination. Discov Med 6: 175-181.
55. Surviladze Z, Dziduszko A, Ozbun MA (2012) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS pathogens 8: e1002519.
56. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. Journal of virology 83: 2067-2074.
57. Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, et al. (2011) Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 20: 325-341.
58. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17-27. (Pubitemid 38737395)